1. LBA3 Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (aNSCLC): CheckMate 227 - part 2 final analysis. (15th December 2019) Authors: Paz-Ares, L; Ciuleanu, T E; Yu, X; Salman, P; Pluzanski, A; Nagrial, A; Havel, L; Kowalyszyn, R; Audigier-Valette, C; Wu, Y-L; Borghaei, H; Hellmann, M D; Brahmer, J; Reck, M; Ramalingam, S; Zhang, L; Bhagavatheeswaran, P; Nathan, F E; O'Byrne, K J Journal: Annals of oncology Issue: Volume 30(2019)Supplement 11 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. (2nd February 2018) Authors: Vokes, E E; Ready, N; Felip, E; Horn, L; Burgio, M A; Antonia, S J; Arén Frontera, O; Gettinger, S; Holgado, E; Spigel, D; Waterhouse, D; Domine, M; Garassino, M; Chow, L Q M; Blumenschein, G; Barlesi, F; Coudert, B; Gainor, J; Arrieta, O; Brahmer, J Journal: Annals of oncology Issue: Volume 29:Number 4(2018) Page Start: 959 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗